The peptide sequences were recovered directly from sorted cells by PCR and cloned into lentiviral vectors to construct libraries for next round selection
Ozempic and Wegovy are registered trademarks of Novo Nordisk
CMS has already announced negotiated prices under the Medicare Drug Price Negotiation Program that take effect in 2027
Turicibacter metabolizes bile acid and lipid metabolism also produces SCFA
Some aspects of the research appear promising, while others remain unproven: What appears promising so far: Reduced substance-seeking behavior observed in animal models Anecdotal and observational reports of decreased cravings in some individuals Growing scientific interest in shared reward pathways between appetite and addiction What remains unproven or unclear: Whether observed effects lead to sustained recovery outcomes How GLP-1s affect the psychological and social dimensions of addiction Whether benefits, if present, are consistent across substances or populations Differences in study design also limit interpretation: Animal trials do not reliably predict human outcomes Observational data cannot establish causation Controlled human trials remain small, limited, and inconsistent Safety considerations are equally important and must be weighed carefully: Common side effects include nausea, appetite suppression, and gastrointestinal distress Changes in appetite or weight may interact with existing mental health symptoms For individuals with eating disorders, appetite-suppressing effects may pose particular risks Given these uncertainties, GLP-1 medications should not replace evidence-based addiction treatments
But heres something many people dont realize: Your body already knows how to make GLP-1
